NCT00491179 - Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions

Chronic Hepatitis CHemodialysis

Interventions

DRUG

Pegylated interferon alfa-2a and ribavirin

Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks

DRUG

Pegylated interferon alfa-2a and ribavirin

Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks

Trial Locations (1)

National Taiwan University Hospital, Taipei

All Listed Sponsors

collaborator

National Science and Technology Council, Taiwan

OTHER_GOV

collaborator

Department of Health, Executive Yuan, R.O.C. (Taiwan)

OTHER_GOV

lead

National Taiwan University Hospital

OTHER